Skip to main content
main-content

08-12-2019 | Haematology | Video

ASH 2019 | Young AML patients respond well to venetoclax, high-dose chemotherapy combination

Seth Karol talks to us about his study of the B-cell lymphoma 2 inhibitor venetoclax showing a good response when combined with cytarabine in children and young adults with relapsed or refractory acute myeloid leukaemia (3:15).

Funding for independent interviews at ASH 2019 was provided by F. Hoffmann-La Roche Ltd, Basel, Switzerland.

See the research in context now

with trial summaries, expert opinion and congress coverage

Image Credits